Prescription platform ZappRx has raised $5.6m in a series A round that has taken its overall funding to almost $9m.
US-based prescription platform ZappRx has closed a $5.6m series A round backed by investors including SR One, the corporate venturing arm of healthcare company GlaxoSmithKline, TechCrunch has reported.
The round also included venture capital firm Atlas Venture, which took part in ZappRx’s $1m seed round in January 2014 alongside SR One and angel investors including Terry Meguid, David Hamamoto, Sean Trigony and James Glimm.
Founded in 2012, ZappRx has developed a platform through which health care providers, patients and pharmacists…
